Registered title, quoted from ClinicalTrials.gov
Impact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast Cancer Patients Undergoing Home CDK4/6 Inhibitor Therapy
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07409298, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to 80 years; sex: all
Registered eligibility fields
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Inclusion criterion 4
Other malignant tumors within the past 5 years (excluding specific cured carcinomas).
Exclusion criterion 3
Pregnant or breastfeeding women.
Exclusion criterion 4
Positive baseline pregnancy test for women of childbearing potential.
Exclusion criterion 5
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07409298, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Females aged ≥ 18 years, regardless of menopausal status.
- Diagnosis of HR+/HER2- breast cancer.
- Currently receiving or scheduled to receive CDK4/6 inhibitor therapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- No history of severe psychiatric disorders (e.g., bipolar disorder, schizophrenia).
- Baseline psychological state sufficient to understand and participate in psychological interventions.
- Currently engaged in a rehabilitation plan, including exercise therapy and physical therapy.
- Willingness to provide written informed consent.
- Capability to perform online operations via smartphone or computer.
Exclusion Criteria:
- Severe complications (e.g., heart disease, severe hepatic or renal dysfunction) that render the patient unable to tolerate CDK4/6i therapy.
- History of severe psychiatric illness (e.g., severe depression, bipolar disorder, or schizophrenia) that precludes self-assessment.
- Other malignant tumors within the past 5 years (excluding specific cured carcinomas).
- Pregnant or breastfeeding women.
- Positive baseline pregnancy test for women of childbearing potential.
- Inability to adapt to or intolerance of the AI virtual doctor's intervention formats.
- Any other condition that the investigator deems unsuitable for participation in the study.
Quoted from ClinicalTrials.gov, NCT07409298, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07409298, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.